Pay-For-Delay Deals Remain In FTC's Crosshairs

Law360, New York (April 23, 2010, 6:27 PM EDT) -- Pay-for-delay settlements between name-brand drugmakers and their generics rivals are still a major target for the Federal Trade Commission's competition enforcers, the agency said Friday in its annual report.

FTC Chairman Jon Leibowitz named pay-for-delays a “top priority” in the report, a comprehensive look at the past fiscal year for the commission.

“We will press to eliminate anti-competitive pay-for-delay patent settlements that deprive consumers of low-cost drugs,” the FTC said in a forward-looking section of the report, after singling out the settlements as "unconscionable" in the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.